Clinical Trial Update: The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation [Phase 3]

View source ↗

Summary

Phase 3 trial of CB-5945 for opioid-induced constipation was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• CB-5945 (CB-5945)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Opioid-Induced Constipation | Phase 3 | Status: TERMINATED | Results posted: 2015-06-15